ISSUE: Adrian Towse will moderate the panel and introduce the session with an account of recent HTA reforms globally, and the evolution of patient centricity in healthcare systems such as Canada and the UK. Professor Ikeda will then share his views on what can be learned from HTA processes overseas, including other Asian countries, and comment on any important aspects unique to Japan in patient-centered decision-making processes both in the current and future HTA reforms. Dr. Kobayashi will voice his learnings from industry’s cost-effectiveness data submissions in the HTA-pilot programme that started in April 2016, and discuss when and how the industry could take a more patient-centered approach in a future HTA-based process in Japan. Finally, Durhane Wong-Rieder will introduce the patient perspective, bringing in patient outcomes of interest and real examples from an international perspective. Alternative methodologies to e.g. CEA will be discussed, addressing patient benefit in the context of the Japanese reform. During the debate, Adrian will allow audience questions and other perspectives throughout OVERVIEW: The Japanese HTA reform is nascent, enabling a significant change in value based assessments and consequent decision making of patient access to interventions. As with any emerging HTAs, it is crucial to consider which methodologies and value framework would be most appropriate for the established healthcare system, and whether there are alternative models to measure value that fits with current praxis that also embed the patient perspective. The debate will center around how the patient voice is, or could be, included in future methodologies and processes, and at what point to factor this into HTA and broader healthcare system decisions. Discussions will also look to understand the motivation to link HTA with Regulatory pathways similarly to Canada, and the inclusion of the patient in established HTA processes in e.g. the UK and Canada